Monte Rosa Therapeutics, Inc. (GLUE)
$13.38-$0.94 (-6.56%) Today
Markus Warmuth - Officer
Jennifer Champoux - Officer
Sharon Townson - OfficerSharon Townson - Officer
Filip Janku - OfficerFilip Janku - Officer
Anthony M. ManningFilip Janku - OfficerMonte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 16 | 104,920 | $2.27M |
| Grant or award | 7 | 180,600 | |
| Option exercise | 24 | 168,218 | |
| Other acquisition / disposition | 3 | 1,030,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
42 Form 4 filings on record, the earliest from Oct 30, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Edmund Dunn - Officer | Option exercise | Common Stock | 25,164 | $13.41 | $337K | |
| Edmund Dunn - Officer | Option exercise | Common Stock | 536 | $13.41 | $7K | |
| Edmund Dunn - Officer | Open-market sale | Common Stock | 536 | $17.50 | $9K | |
| Edmund Dunn - Officer | Open-market sale | Common Stock | 25,164 | $18.10 | $456K | |
| Edmund Dunn - Officer | Option exercise | Stock Option (Right to Buy) | 25,164 | $0.00 | - | |
| Edmund Dunn - Officer | Option exercise | Stock Option (Right to Buy) | 536 | $0.00 | - | |
| Filip Janku - Officer | Open-market sale | Common Stock | 9,189 | $19.50 | $179K | |
| Markus Warmuth - Officer | Open-market sale | Common Stock | 3,707 | $23.24 | $86K | |
| Markus Warmuth - Officer | Open-market sale | Common Stock | 1,450 | $23.88 | $35K | |
| Markus Warmuth - Officer | Open-market sale | Common Stock | 309 | $24.57 | $8K | |
| Philip Nickson - Officer | Grant or award | Common Stock | 28,000 | - | - | |
| Philip Nickson - Officer | Open-market sale | Common Stock | 3,155 | $15.17 | $48K | |
| Philip Nickson - Officer | Grant or award | Stock Option (Right to Buy) | 126,000 | $0.00 | - | |
| Jennifer Champoux - Officer | Grant or award | Common Stock | 35,000 | - | - | |
| Jennifer Champoux - Officer | Open-market sale | Common Stock | 2,629 | $15.17 | $40K | |
| Jennifer Champoux - Officer | Grant or award | Stock Option (Right to Buy) | 158,000 | $0.00 | - | |
| Edmund Dunn - Officer | Open-market sale | Common Stock | 1,039 | $15.17 | $16K | |
| Markus Warmuth - Officer | Grant or award | Common Stock | 90,000 | - | - | |
| Markus Warmuth - Officer | Open-market sale | Common Stock | 10,135 | $15.17 | $154K | |
| Markus Warmuth - Officer | Grant or award | Stock Option (Right to Buy) | 406,000 | $0.00 | - | |
| Filip Janku - Officer | Grant or award | Common Stock | 31,000 | - | - | |
| Filip Janku - Officer | Open-market sale | Common Stock | 3,155 | $15.17 | $48K | |
| Filip Janku - Officer | Grant or award | Stock Option (Right to Buy) | 139,000 | $0.00 | - | |
| Sharon Townson - Officer | Grant or award | Common Stock | 35,000 | - | - | |
| Sharon Townson - Officer | Open-market sale | Common Stock | 3,155 | $15.17 | $48K | |
| Sharon Townson - Officer | Grant or award | Stock Option (Right to Buy) | 158,000 | $0.00 | - | |
| Andrew N. Schiff | Grant or award | Stock Option (Right to Buy) | 30,700 | $0.00 | - | |
| Eric A. Hughes | Grant or award | Stock Option (Right to Buy) | 44,200 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 89,990 | $9.66 | $869K | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 1,019,867 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 20,397 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 20,397 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 17,595 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 17,595 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 366,590 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 5,499 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 5,499 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 5,454 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Other | Common Stock | 5,454 | $0.00 | - | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 52,305 | $9.08 | $475K | |
| Versant Venture Capital VI, L.P. | Open-market sale | Common Stock | 15,600 | $9.41 | $147K |
This is as far as the anonymous view goes. Create a free account for all 42 GLUE filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Monte Rosa Therapeutics, Inc. (GLUE) had 21 insider filings in the last 90 days, with the most recent on 2026-07-17. The full record for GLUE runs to 42 Form 4 filings, the earliest from 2024-10-30. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of GLUE were filed in the last 90 days.
16 insider sales of GLUE were filed in the last 90 days, totaling $2.27M.
This page tracks GLUE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GLUE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
